Zschaebitz, Stefanie and Erlmeier, Franziska and Stoehr, Christine and Herrmann, Edwin and Polifka, Iris and Agaimy, Abbas and Trojan, Lutz and Stroebel, Philipp and Becker, Frank and Wuelfing, Christian and Barth, Peter and Stoeckle, Michael and Staehler, Michael and Stief, Christian and Haferkamp, Axel and Hohenfellner, Markus and Macher-Goeppinger, Stephan and Wullich, Bernd and Noldus, Joachim and Brenner, Walburgis and Roos, Frederik C. and Walter, Bernhard and Otto, Wolfgang and Burger, Maximilian and Schrader, Andres Jan and Mondorf, Yvonne and Hartmann, Arndt and Ivanyi, Philipp and Steffens, Sandra (2022) Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort. JOURNAL OF CANCER, 13 (5). pp. 1706-1712. ISSN 1837-9664,
Full text not available from this repository. (Request a copy)Abstract
Prostate specific membrane antigen (PSMA) is an emerging diagnostic and therapeutic target in prostate cancer. 68 Ga-PSMA-labeled hybrid imaging is used for the detection of prostate primary tumors and metastases. Therapeutic applications such as Lutetium-177 PSMA radionuclide therapy or bispecific antibodies that target PSMA are currently under investigation within clinical trials. The expression of PSMA, however, is not specific to prostate-tissue. It has been described in the neovascular endothelium of different types of cancer such as breast cancer, and clear cell renal cell carcinoma (ccRCC). The aim of this study was to analyze PSMA expression in papillary RCC (pRCC) type 1 and type 2, the most common non-ccRCC subtypes, and to evaluate the potential of PSMA-targeted imaging and treatment in pRCC. Formalin-fixed, paraffin-embedded tissue samples of primary tumors were analyzed for PSMA expression by immunohistochemistry. Out of n=374 pRCC specimens from the multicenter PANZAR consortium, n=197 pRCC type 1 and n=110 type 2 specimens were eligible for analysis and correlated with clinical data. In pRCC type 1 PSMA staining was positive in 4 of 197 (2.0%) samples whereas none (0/110) of the pRCC type 2 samples were positive for PSMA in this large cohort of pRCC patients. No significant PSMA expression was detected in pRCC. Reflecting current clinical evaluation of PMSA expression in RCC do not encourage further analysis in papillary subtypes.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ; prostate specific membrane antigen; papillary renal cell carcinoma; kidney cancer |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 12 Dec 2023 14:24 |
| Last Modified: | 12 Dec 2023 14:24 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58730 |
Actions (login required)
 |
View Item |
